Results 91 to 100 of about 12,336,620 (246)

A functional prognostic model predicts progression-free survival in patients with relapsed chronic lymphocytic leukemia treated with ibrutinib + venetoclax. [PDF]

Hemasphere
Abstract Targeted therapies have improved outcomes for patients with chronic lymphocytic leukemia (CLL); yet, not all achieve durable responses. Existing prognostic models, developed for chemoimmunotherapy, have limited predictive value for newer targeted combinations.
Hermansen JU, Kong W, Brodersen AM, Yin Y, Urban A, Rein ID, He L, Agius R, Teglgaard RS, Rousu J, Brieghel C, Kersting S, Levin MD, Tran HTT, Mattsson M, Ranti J, Veldhuis GJ, da Cunha-Bang C, Mous R, Dubois J, Kater AP, Enserink JM, Niemann CU, Aittokallio T, Skånland SS.   +24 more
europepmc   +2 more sources

Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells.

, 2005
Analysis of peripheral blood (>85% CD19+/CD5+ B) lymphocytes, obtained from 44 patients affected by B chronic lymphoid leukemia (B-CLL), showed that surface TNF-related apoptosis inducing ligand (TRAIL) was expressed in all samples and at higher levels ...
CELEGHINI C, MICHELUTTI A, MASOLINI P, FANIN R, SECCHIERO, Paola, ZAULI, Giorgio, BARBAROTTO, Elisa, TIRIBELLI M   +7 more
core   +2 more sources

Intracellular tumor necrosis factor production by T- and B-cells in B-cell chronic lymphocytic leukemia

Haematologica, 2002
BACKGROUND AND OBJECTIVES: The pathogenesis of B-cell chronic lymphocytic leukemia (B-CLL) has been linked with the production and activity of certain growth factors.
A Bojarska-Junak, J Rolinski, E Wasik-Szczepaneko, Z Kaluzny, A Dmoszynska   +4 more
doaj  

Prospective Short‐ and Long‐Term Changes in Cardiometabolic Risk Markers Following Gender‐Affirming Hormone Therapy

Andrology, EarlyView.
ABSTRACT Introduction Gender‐affirming hormone therapy (GAHT) may be associated with increased cardiometabolic disease (CMD) risk. Prospective CMD risk screening is recommended, but long‐term data are needed regarding changes in CMD markers. Objectives To evaluate prospective changes in CMD risk markers during GAHT.
Louise Lehmann Christensen, Camilla Viola Palm, Marianne S. Andersen, Guy T'Sjoen, Jan Frystyk, Tine Taulbjerg Kristensen, Rikke Hjortebjerg, Dorte Glintborg   +7 more
wiley   +1 more source

High-dimensional spectral flow cytometry uncovers progressive T-cell exhaustion and myeloid cell reprogramming in a CLL mouse model. [PDF]

Hemasphere
Abstract Chronic lymphocytic leukemia (CLL) exhibits marked clinical heterogeneity that cannot be fully explained by genetic alterations, underscoring the critical role of the tumor microenvironment in disease progression and therapeutic resistance.
Briesch H, Coelho M, Floerchinger A, Borysovych Y, Aubert N, Medina-Gil D, Breitinger M, Zapatka M, Autenrieth SE, Seiffert M.   +9 more
europepmc   +2 more sources

Long‐Term Outcomes After Elective Splenectomy for Haematological Disease: A 27‐Year Single‐Centre Study

ANZ Journal of Surgery, EarlyView.
Splenectomy is a safe and effective treatment option in selected patients with haematological disease, despite declining referrals over the last 27 years in the era of targeted therapies. Outcomes are favourable when performed laparoscopically and long‐term follow‐up demonstrates sustained haematologic benefit in surviving patients.
Salil Dutt Barrett, Anthony Downhill, Douglas Greer, William Stevenson, Ian Kerridge, Chris Ward, Matthew Greenwood, Naomi Mackinlay, Luke Coyle, Thomas J. Hugh   +9 more
wiley   +1 more source

Mosaic chromosomal alterations and relation to haematological cancer in two large Danish cohorts

British Journal of Haematology, EarlyView.
Summary Mosaic chromosomal alterations (mCAs) are large somatic gains, losses and copy‐neutral loss of heterozygosity identified in the peripheral blood, which represent a relatively unexplored spectrum of clonal haematopoiesis. We aimed to describe mCAs in two large Danish cohorts with extensive long‐term registry‐based follow‐up and examine ...
Cecilie Velsoe Maeng, Pei Meng, Mathias Heldbo, Olafur Davidsson, Morten Munk Johansen, Sigrún Thorsteinsdóttir, Jojo Biel‐Nielsen Dietz, Ragnar Pétur Kristjansson, Ole Birger Vesterager Pedersen, Erik Sørensen, Christian Erikstrup, Christina Mikkelsen, Nanna Brøns, Henrik Ullum, Bitten Aagaard, Mie Topholm Bruun, Estrid Høgdall, DBDS Research Consortium, CHB Research Consortium, Bo Porse, Simon Husby, Sisse R. Ostrowski, Henrik Hjalgrim, Kirsten Grønbæk   +23 more
wiley   +1 more source

The mechanisms of Ara-C-induced apoptosis of resting B-chronic lymphocytic leukemia cells

Haematologica, 2006
BACKGROUND AND OBJECTIVES: Cytarabine (Ara-C) is commonly used for the treatment of acute leukemia. Incorporation of Ara-C into DNA is a key event in the mechanism of killing of proliferating leukemic cells.
JF de Vries, JH Falkenburg, R Willemze, RM Barge   +3 more
doaj  

Second primary cancers in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia—cumulative burden without generalized excess cancer risk

British Journal of Haematology, EarlyView.
Summary Second primary cancers (SPCs) are a survivorship concern in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia (LPL/WM), but estimates may be influenced by competing mortality and surveillance. We assessed cumulative incidence, relative risk and predictors of SPCs. We studied 521 patients diagnosed with LPL/WM in Region Zealand, Denmark,
Lars Munksgaard, Lars Moeller Pedersen, Lise Mette Rahbek Gjerdrum   +2 more
wiley   +1 more source

High-throughput analysis of the T cell receptor gene repertoire in low-count monoclonal B cell lymphocytosis reveals a distinct profile from chronic lymphocytic leukemia

Haematologica, 2020
Andreas Agathangelidis, Chrysi Galigalidou, Lydia Scarfò, Theodoros Moysiadis, Alessandra Rovida, Elisavet Vlachonikola, Electra Sofou, Fotis Psomopoulos, Anna Vardi, Pamela Ranghetti, Alexandra Siorenta, Alex Galanis, Kostas Stamatopoulos, Anastasia Chatzidimitriou, Paolo Ghia   +14 more
doaj   +1 more source